Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction on Friday, March 20th. The shares were sold at an average price of $13.37, for a total value of $254,832.20. Following the completion of the transaction, the chief operating officer owned 486,244 shares in the company, valued at $6,501,082.28. The trade was a 3.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Julie Rubinstein also recently made the following trade(s):
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
- On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.
- On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total transaction of $457,617.39.
- On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total transaction of $285,672.80.
- On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
- On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.
Adaptive Biotechnologies Stock Up 0.6%
Adaptive Biotechnologies stock opened at $13.66 on Tuesday. Adaptive Biotechnologies Corporation has a 52-week low of $6.68 and a 52-week high of $20.76. The firm has a fifty day moving average of $16.19 and a 200-day moving average of $15.91. The firm has a market capitalization of $2.10 billion, a P/E ratio of -34.15 and a beta of 2.19.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the business posted ($0.23) EPS. The business's quarterly revenue was up 51.0% on a year-over-year basis. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.
Institutional Trading of Adaptive Biotechnologies
Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth about $28,000. Sound Income Strategies LLC purchased a new position in Adaptive Biotechnologies in the third quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. grew its stake in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the 4th quarter valued at approximately $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Friday, February 6th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research report on Friday, February 6th. TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.25.
Check Out Our Latest Report on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
